Why Bausch + Lomb stopped its BL1107 neuroprotective glaucoma eye-drop program
Bausch + Lomb is dropping BL1107 eye drops after a Phase 2 glaucoma miss and redirecting the asset toward a geographic atrophy implant.
Pharma & Biotech
Medical Devices & Diagnostics
Is Glaukos building a multi-franchise ophthalmology platform through Epioxa and glaucoma implants?
Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.
Medical Devices & Diagnostics
Can smaller eyedrops improve glaucoma outcomes? Nanodropper data make the case
Nanodropper’s glaucoma study suggests microdrops may improve pressure control and reduce waste. Read what this could mean for eye care.
Pharma & Biotech
What Nicox SA’s NCX 470 presentations signal for nitric oxide–based eye therapies
Discover how Nicox SA’s NCX 470 Phase 3 data could reshape glaucoma treatment and regulatory strategy. Read the full analysis.